Accountable.US Statement on House Republicans Burying Trump AG Pick Matt Gaetz’ Ethics Report
President-elect Trump’s Nomination of Dr. Oz Means Health Care At Risk for Seniors and Vulnerable Americans
At Least 5 People Associated with Project 2025 Tapped to Serve in the Trump Administration
Senate Hearing Highlights Need to End Visa-Mastercard Duopoly to Bring Competition, Lower Fees for Consumers and Small Business Owners
Trump and Republicans in Congress Double Down on Failed Economic System that Works for the Wealthy and Stiffs the Working Class
Site Menu

WASHINGTON, DC — Today, the US District Court for the District of Delaware released its decision in AstraZeneca Pharmaceuticals LP et al. v. Becerra et al., ruling against the pharmaceutical giant in its attempt to ban Medicare from negotiating lower drug prices with manufacturers under the Inflation Reduction Act. Accountable.US Executive Director Tony Carrk issued the following statement in response: 

“

Big drug company executives are stopping at nothing to price gouge Americans and pad their profits. First they spent millions to stop the Inflation Reduction Act’s Medicare price negotiation authority and failed. Now they are trying to do it by clogging the judicial system with meritless lawsuits. Today’s ruling is a victory for the Biden administration’s historic cost-lowering program and for seniors who need lower prescription drug costs.”

The decision follows a ruling earlier this month in the US District Court for the Western District of Texas that tossed out a lawsuit against the Biden administration brought by the Pharmaceutical Research and Manufacturers of America (PhRMA) and its allies that also sought to block Medicare from negotiating lower drug prices. 

More on Gross Pharma Profiteering From Accountable.US: 

back to top